Literature DB >> 16412059

In vitro responses of human peripheral blood mononuclear cells to whole-cell, particulate and soluble extracts of Leishmania promastigotes.

E Telino1, P M De Luca, D C S Matos, R B Azeredo-Coutinho, M N Meirelles, F Conceição-Silva, A Schubach, S C F Mendonça.   

Abstract

Whole-cell and soluble extracts of Leishmania promastigotes have both been used as skin test antigens and have also been tested as vaccine candidates. However, the differences in antigenicity between soluble and particulate Leishmania fractions are not known. We evaluated in vitro responses of PBMC from 30 American tegumentary leishmaniasis (ATL) patients and seven noninfected donors to different antigen preparations from Leishmania promastigotes, namely Leishmania amazonensis and L. braziliensis whole-cell extracts, as well as soluble and particulate fractions of L. amazonensis. All Leishmania antigen preparations stimulated significantly higher proliferation and interferon (IFN)-gamma production (but not interleukin (IL)-10 production) in PBMC from the leishmaniasis patients than in cells from the control subjects. The L. braziliensis whole-cell extract stimulated significantly higher cell proliferation and IFN-gamma production than the L. amazonensis whole-cell extract in the group of patients but not in the control group. This result can be explained by the fact that the patients were infected with L. braziliensis. Again in the group of patients, the PBMC proliferative responses as well as the levels of IFN-gamma and IL-10 stimulated by L. amazonensis whole-cell extract were significantly greater than those elicited by the L. amazonensis soluble fraction but were not significantly different from those elicited by the L. amazonensis particulate fraction. We found a higher antigenicity of the particulate fraction as compared to the soluble fraction, what suggests that the antigens present in the particulate fraction account for most of the antigenicity of whole-cell Leishmania promastigote antigen extracts.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16412059      PMCID: PMC1809595          DOI: 10.1111/j.1365-2249.2006.02995.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  41 in total

1.  Differential induction of cellular responses by live and dead Leishmania promastigotes in healthy donors.

Authors:  S Nylén; U Mörtberg; D Kovalenko; I Satti; K Engström; M Bakhiet; H Akuffo
Journal:  Clin Exp Immunol       Date:  2001-04       Impact factor: 4.330

2.  Randomized, double-blind, placebo-controlled study on the immunogenicity of the leishmanin skin test.

Authors:  P M De Luca; W Mayrink; M A Santiago; R Nogueira; F Conceição-Silva; G Mélo; S C F Mendonça
Journal:  Trans R Soc Trop Med Hyg       Date:  2003 Nov-Dec       Impact factor: 2.184

3.  Phase 1 study of an inactivated vaccine against American tegumentary leishmaniasis in normal volunteers in Brazil.

Authors:  K B Marzochi; M A Marzochi; A F Silva; N Grativol; R Duarte; E M Confort; F Modabber
Journal:  Mem Inst Oswaldo Cruz       Date:  1998 Mar-Apr       Impact factor: 2.743

4.  Differential interferon- gamma production characterizes the cytokine responses to Leishmania and Mycobacterium leprae antigens in concomitant mucocutaneous leishmaniasis and lepromatous leprosy.

Authors:  Denise S Matos; Rilza B G Azeredo-Coutinho; Armando Schubach; Fátima Conceição-Silva; Cibele Baptista; João S Moreira; Sergio C F Mendonça
Journal:  Clin Infect Dis       Date:  2004-12-22       Impact factor: 9.079

5.  Immunostimulatory cellular responses of cured Leishmania-infected patients and hamsters against the integral membrane proteins and non-membranous soluble proteins of a recent clinical isolate of Leishmania donovani.

Authors:  R Garg; S K Gupta; P Tripathi; S Naik; S Sundar; A Dube
Journal:  Clin Exp Immunol       Date:  2005-04       Impact factor: 4.330

6.  Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: evidence for mixed Th1- and Th2-like responses in visceral leishmaniasis.

Authors:  Rajatava Basu; Suniti Bhaumik; Jayati Mookerjee Basu; Kshudiram Naskar; Tripti De; Syamal Roy
Journal:  J Immunol       Date:  2005-06-01       Impact factor: 5.422

7.  Evaluation of the stability and immunogenicity of autoclaved and nonautoclaved preparations of a vaccine against American tegumentary leishmaniasis.

Authors:  P M De Luca; W Mayrink; C R Alves; S G Coutinho; M P Oliveira; A L Bertho; V P Toledo; C A Costa; O Genaro; S C Mendonça
Journal:  Vaccine       Date:  1999-03-05       Impact factor: 3.641

8.  American tegumentary leishmaniasis (ATL) in Rio de Janeiro State, Brazil: main clinical and epidemiologic characteristics.

Authors:  M P de Oliveira-Neto; M S Mattos; M A Perez; A M Da-Cruz; O Fernandes; J Moreira; S C Gonçalves-Costa; L R Brahin; C R Menezes; C Pirmez
Journal:  Int J Dermatol       Date:  2000-07       Impact factor: 2.736

9.  Failure of a killed Leishmania amazonensis vaccine against American cutaneous leishmaniasis in Colombia.

Authors:  Iván D Vélez; Katherine Gilchrist; María P Arbelaez; Carlos A Rojas; Juan A Puerta; Carlos M F Antunes; Fabio Zicker; Farrokh Modabber
Journal:  Trans R Soc Trop Med Hyg       Date:  2005-08       Impact factor: 2.184

Review 10.  Lipid based particulate formulations for the delivery of antigen.

Authors:  Melissa J Copland; Thomas Rades; Nigel M Davies; Margaret A Baird
Journal:  Immunol Cell Biol       Date:  2005-04       Impact factor: 5.126

View more
  8 in total

1.  Leishmania (Viannia) shawi purified antigens confer protection against murine cutaneous leishmaniasis.

Authors:  Luiz Felipe Domingues Passero; Ana Kely Carvalho; Maria Luiza A C Bordon; Alexis Bonfim-Melo; Marcos Hikari Toyama; Carlos Eduardo Pereira Corbett; Márcia Dalastra Laurenti
Journal:  Inflamm Res       Date:  2011-12-14       Impact factor: 4.575

2.  Multifunctional CD4⁺ T cells in patients with American cutaneous leishmaniasis.

Authors:  A B B Macedo; J C Sánchez-Arcila; A O Schubach; S C F Mendonça; A Marins-Dos-Santos; M de Fatima Madeira; T Gagini; M I F Pimentel; P M De Luca
Journal:  Clin Exp Immunol       Date:  2012-03       Impact factor: 4.330

3.  Cellular immune response profile in patients with American tegumentary leishmaniasis prior and post chemotherapy treatment.

Authors:  Luiza C Reis; Maria Edilenza F Brito; Marina A Souza; Angela C R Medeiros; Claudio J Silva; Carlos F Luna; Valéria R A Pereira
Journal:  J Clin Lab Anal       Date:  2009       Impact factor: 2.352

4.  Contrasting human cytokine responses to promastigote whole-cell extract and the Leishmania analogue receptor for activated C kinase antigen of L. amazonensis in natural infection versus immunization.

Authors:  R B G Azeredo-Coutinho; D C S Matos; G G R Armôa; R M Maia; A Schubach; W Mayrink; S C F Mendonça
Journal:  Clin Exp Immunol       Date:  2008-07-08       Impact factor: 4.330

5.  American tegumentary leishmaniasis: T-cell differentiation profile of cutaneous and mucosal forms-co-infection with Trypanosoma cruzi.

Authors:  Cecilia Parodi; María F García Bustos; Alejandra Barrio; Federico Ramos; Ana G González Prieto; María C Mora; Patricia Baré; Miguel A Basombrío; María M de Elizalde de Bracco
Journal:  Med Microbiol Immunol       Date:  2016-04-04       Impact factor: 3.402

6.  Interleukin-10-dependent down-regulation of interferon-gamma response to Leishmania by Mycobacterium leprae antigens during the clinical course of a coinfection.

Authors:  R B G Azeredo-Coutinho; D C S Matos; J A C Nery; C M Valete-Rosalino; S C F Mendonça
Journal:  Braz J Med Biol Res       Date:  2012-05-10       Impact factor: 2.590

Review 7.  Cutaneous Leishmaniasis Vaccination: A Matter of Quality.

Authors:  Paula Mello De Luca; Amanda Beatriz Barreto Macedo
Journal:  Front Immunol       Date:  2016-04-21       Impact factor: 7.561

8.  Ultradeformable Archaeosomes for Needle Free Nanovaccination with Leishmania braziliensis Antigens.

Authors:  Leticia H Higa; Laura Arnal; Mónica Vermeulen; Ana Paula Perez; Priscila Schilrreff; Cecilia Mundiña-Weilenmann; Osvaldo Yantorno; María Elena Vela; María José Morilla; Eder Lilia Romero
Journal:  PLoS One       Date:  2016-03-02       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.